SCHEDULE: iTeos Therapeutics Agrees to Acquisition by Concentra Biosciences in Cash and CVR Deal

iTeos Therapeutics, Inc. has entered into a definitive merger agreement to be acquired by Concentra Biosciences, LLC for $10.047 per share in cash plus one contingent value right.

Summary

• iTeos Therapeutics, Inc. entered into an Agreement and Plan of Merger with Concentra Biosciences, LLC and Concentra Merger Sub VIII, Inc. on July 18, 2025.
• The acquisition will occur through a tender offer for all outstanding shares of iTeos common stock, followed by a merger.
• Shareholders will receive $10.047 in cash per share and one Contingent Value Right (CVR).
• Closing of the tender offer is subject to conditions, including valid tenders of at least one share more than 50% of outstanding common stock and a Closing Net Cash of no less than $475 million.
• Tang Capital Partners, LP provided a Limited Guaranty to iTeos for certain obligations of Concentra and Merger Sub, capped at $465.0 million under the Merger Agreement and CVR Proceeds plus CVR Expense Cap under the CVR Agreement.
• The CVR entitles holders to contingent cash payments: 100% of Closing Net Cash exceeding $475 million (adjusted) and 80% of Net Proceeds from the disposition of specific 'CVR Products' (EOS-984, EOS-215, preclinical obesity program, PTPNI1/2 program, and certain IP-covered products).
• Dispositions of CVR Products must occur within a 6-month 'Disposition Period' following the Merger Closing Date, with proceeds received within 8 years thereafter.
• If no dispositions occur by the 6-month anniversary, no CVR payment will be made for dispositions.
• Concentra is obligated to use commercially reasonable efforts, up to a $350,000 'CVR Expense Cap', to facilitate CVR Product dispositions and maintenance.
• Reporting persons (Tang Capital Management, LLC, Kevin Tang, Tang Capital Partners, LP, and Tang Capital Partners International, LP) collectively beneficially own 3,826,692 shares, representing 9.99% of iTeos's common stock outstanding as of April 22, 2025.

Sentiment

Score: 7

Explanation: The sentiment is generally positive as the filing announces a definitive acquisition providing a cash premium and potential upside via CVRs, offering certainty to shareholders. However, the CVR's value is highly contingent and speculative, introducing some uncertainty.

Positives

• The definitive merger agreement provides a clear exit strategy and certainty for iTeos Therapeutics shareholders.
• The cash component of $10.047 per share offers immediate liquidity and a premium to shareholders.
• The Contingent Value Right (CVR) provides shareholders with potential upside participation in the future monetization of specific pipeline assets, including EOS-984 and EOS-215.
• A Limited Guaranty from Tang Capital Partners, LP provides some financial assurance regarding Concentra's obligations under the merger and CVR agreements.

Negatives

• The value of the CVR is highly contingent and speculative, dependent on future events such as the successful disposition of CVR Products and the final Closing Net Cash amount.
• The 'Disposition Period' for CVR Products is limited to six months, which may restrict the ability to maximize value from these assets.
• There will be no CVR payment related to dispositions if no such dispositions occur by the six-month anniversary of the Merger Closing Date.
• The 'commercially reasonable efforts' for CVR Product disposition are capped by a relatively small CVR Expense Cap of $350,000, which might limit extensive efforts.

Risks

• The CVR payments are highly speculative and depend on the successful disposition of specific CVR Products within a limited 6-month window.
• The final value of the CVR is subject to the calculation of 'Closing Net Cash' and potential adjustments.
• There is a risk of no CVR payment for dispositions if no such transactions are completed by the six-month anniversary of the Merger Closing Date.
• The 'commercially reasonable efforts' clause for CVR Product disposition is subject to interpretation and limited by the $350,000 CVR Expense Cap, potentially impacting the likelihood or value of dispositions.
• The completion of the tender offer is contingent on meeting specific conditions, including the number of shares tendered and the Closing Net Cash amount.

Future Outlook

The future outlook for iTeos Therapeutics as an independent entity is defined by its pending acquisition by Concentra Biosciences. For shareholders, the future value beyond the cash consideration will depend entirely on the performance and successful disposition of specific CVR Products (EOS-984, EOS-215, preclinical obesity program, PTPNI1/2 program) within a 6-month period following the merger, and the final determination of Closing Net Cash. Concentra is committed to using commercially reasonable efforts, up to a $350,000 cap, to facilitate these dispositions.

Industry Context

This acquisition highlights the ongoing trend of consolidation within the biotechnology and pharmaceutical sectors, particularly for companies with promising, albeit early-stage, clinical assets. The use of a Contingent Value Right (CVR) is a common mechanism in biotech M&A to bridge valuation gaps between buyers and sellers, especially when the value of pipeline assets is uncertain or requires further development/monetization efforts. The focus on oncology and metabolic disease programs aligns with high-value therapeutic areas attracting significant investment and M&A activity.

Comparison to Industry Standards

• The inclusion of a CVR in this acquisition is a standard practice in biotech M&A, often used when there is significant future value tied to pipeline assets that are not yet fully de-risked or commercialized. For example, Sanofi's acquisition of Kadmon Holdings included a CVR tied to the approval of KD025, and Bristol Myers Squibb's acquisition of MyoKardia included a CVR for mavacamten.
• The specific terms of the CVR, such as the 6-month disposition period and the 80% share of net proceeds, would need to be benchmarked against similar CVR structures in other biotech deals to assess their relative favorability. Without specific comparable deal details within the filing, a direct quantitative comparison of these terms is not feasible.
• The $350,000 CVR Expense Cap for 'commercially reasonable efforts' is a specific term that would be evaluated against similar caps in other CVR agreements to determine if it provides sufficient incentive and resources for the acquirer to maximize the CVR's value.

Related Party Transactions

• Tang Capital Partners, LP, a reporting person and part of the acquiring group led by Kevin Tang, has delivered a Limited Guaranty to iTeos Therapeutics in respect of certain of Concentra's and Merger Sub's obligations under the Merger Agreement and CVR Agreement.

Stakeholder Impact

• Shareholders will receive a fixed cash price of $10.047 per share and one CVR, providing immediate liquidity and potential future upside based on the performance of specific pipeline assets.
• The acquisition will result in iTeos Therapeutics becoming a privately held subsidiary of Concentra Biosciences, impacting its operational and strategic direction.

Next Steps

• Concentra Biosciences and Concentra Merger Sub VIII, Inc. are expected to launch a tender offer for all outstanding shares of iTeos Therapeutics common stock.
• The tender offer will close upon satisfaction of certain conditions, including the minimum tender threshold and the Closing Net Cash requirement.
• Following the tender offer, Concentra Merger Sub VIII, Inc. will merge into iTeos Therapeutics, with iTeos surviving as a subsidiary of Concentra.
• Concentra and Merger Sub are expected to enter into a Contingent Value Rights Agreement with a rights agent at or prior to the time shares are accepted for purchase.
• Concentra is obligated to use commercially reasonable efforts to dispose of CVR Products within six months following the merger closing date to potentially generate CVR payments.

Key Dates

Recommendation

The definitive merger agreement provides a clear exit strategy for existing shareholders at a fixed cash price plus a contingent value right. For current shareholders, holding through the tender offer is the logical step to realize the cash value and retain the CVR for potential future upside. For new investors, the immediate upside is limited to the speculative value of the CVR, making it less attractive for a 'buy' recommendation, as the share price will likely trade close to the cash offer price until the deal closes.

Keywords

iTeos Therapeutics, Concentra Biosciences, Merger, Acquisition, Tender Offer, Contingent Value Right, CVR, EOS-984, EOS-215, Oncology, Biotechnology, Pharmaceuticals, SEC Filing, Kevin Tang, Tang Capital Management